Page last updated: 2024-11-02

pioglitazone and Cardiac Hypertrophy

pioglitazone has been researched along with Cardiac Hypertrophy in 12 studies

Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.

Cardiac Hypertrophy: Enlargement of the HEART due to chamber HYPERTROPHY, an increase in wall thickness without an increase in the number of cells (MYOCYTES, CARDIAC). It is the result of increase in myocyte size, mitochondrial and myofibrillar mass, as well as changes in extracellular matrix.

Research Excerpts

ExcerptRelevanceReference
"To investigate the effects of pioglitazone on cardiac hypertrophy in vitro and in vivo."7.73[Pioglitazone inhibits cardiac hypertrophy of rats in vitro and in vivo]. ( Liu, YX; Wu, SM; Ye, P; Zhang, C, 2005)
"Endothelin-1 (ET-1) causes cardiac hypertrophy, and ET receptor antagonists inhibit the development of cardiac hypertrophy in vitro and in vivo."7.71Peroxisome proliferator-activated receptor-gamma activators inhibit endothelin-1-related cardiac hypertrophy in rats. ( Goto, K; Irukayama-Tomobe, Y; Miyauchi, T; Ogata, T; Sakai, S; Yamaguchi, I, 2002)
" Here we investigated the effect of pioglitazone on angiotensin II (Ang II)-induced cardiac hypertrophy and assessed the potential contribution of adiponectin to the action of pioglitazone on the heart."3.76Evidence for the importance of adiponectin in the cardioprotective effects of pioglitazone. ( Cheng, X; Furukawa, M; Li, P; Murohara, T; Nagata, K; Ohashi, T; Ouchi, N; Shibata, R; Shimano, M; Unno, K, 2010)
"Wild-type cardiomyocyte- and macrophage-specific PPARgamma(-/-) mice were infused with angiotensin II (AngII) to promote cardiac fibrosis and treated with the PPARgamma ligand pioglitazone to determine the roles of cardiomyocyte and macrophage PPARgamma in cardiac fibrosis."3.74Differential roles of cardiomyocyte and macrophage peroxisome proliferator-activated receptor gamma in cardiac fibrosis. ( Caglayan, E; Collins, AR; Erdmann, E; Hsueh, WA; Liu, J; Lyon, CJ; Peterson, LE; Rosenkranz, S; Ross, RS; Stauber, B; Tangirala, RK; Yin, F, 2008)
" Stroke-prone spontaneously hypertensive rats (SHRSP) were orally given pioglitazone, candesartan, or combined pioglitazone and candesartan for 4 weeks to compare their effects on cardiovascular injury."3.74Beneficial effects of pioglitazone on hypertensive cardiovascular injury are enhanced by combination with candesartan. ( Dong, YF; Kataoka, K; Kim-Mitsuyama, S; Matsuba, S; Nakamura, T; Ogawa, H; Tokutomi, Y; Yamamoto, E; Yamashita, T, 2008)
"To investigate the effects of pioglitazone on cardiac hypertrophy in vitro and in vivo."3.73[Pioglitazone inhibits cardiac hypertrophy of rats in vitro and in vivo]. ( Liu, YX; Wu, SM; Ye, P; Zhang, C, 2005)
"Endothelin-1 (ET-1) causes cardiac hypertrophy, and ET receptor antagonists inhibit the development of cardiac hypertrophy in vitro and in vivo."3.71Peroxisome proliferator-activated receptor-gamma activators inhibit endothelin-1-related cardiac hypertrophy in rats. ( Goto, K; Irukayama-Tomobe, Y; Miyauchi, T; Ogata, T; Sakai, S; Yamaguchi, I, 2002)
" In the present study, we examined the role of PPARgamma in angiotensin II (Ang II)-induced hypertrophy of neonatal rat cardiac myocytes and in pressure overload-induced cardiac hypertrophy of mice."3.71Peroxisome proliferator-activated receptor gamma plays a critical role in inhibition of cardiac hypertrophy in vitro and in vivo. ( Asakawa, M; Hasegawa, H; Kadowaki, T; Komuro, I; Kubota, N; Masuda, Y; Nagai, T; Saito, T; Takano, H; Uozumi, H, 2002)
"Rosiglitazone treatment induced volume expansion and CH in wild-type and PPARĪ³ heterozygous knockout (Pparg(+/-)) mice, but not in mice defective for ligand binding (Pparg(P465L/+))."1.40Diuretics prevent thiazolidinedione-induced cardiac hypertrophy without compromising insulin-sensitizing effects in mice. ( Chang, CS; Chen, JY; Ho, LC; Maeda, N; Pandya, K; Sung, JM; Tsai, PJ; Tsai, YS, 2014)

Research

Studies (12)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's7 (58.33)29.6817
2010's5 (41.67)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Wei, WY1
Zhang, N1
Li, LL1
Ma, ZG1
Xu, M1
Yuan, YP1
Deng, W1
Tang, QZ1
Liu, Y2
Yan, X1
Mao, G1
Fang, L1
Zhao, B1
Tang, H1
Wang, N1
Chang, CS1
Tsai, PJ1
Sung, JM1
Chen, JY1
Ho, LC1
Pandya, K1
Maeda, N1
Tsai, YS1
Verschuren, L1
Wielinga, PY1
Kelder, T1
Radonjic, M1
Salic, K1
Kleemann, R1
van Ommen, B1
Kooistra, T1
Caglayan, E1
Stauber, B1
Collins, AR1
Lyon, CJ1
Yin, F1
Liu, J2
Rosenkranz, S1
Erdmann, E1
Peterson, LE1
Ross, RS1
Tangirala, RK1
Hsueh, WA1
Li, P1
Shibata, R1
Unno, K1
Shimano, M1
Furukawa, M1
Ohashi, T1
Cheng, X1
Nagata, K1
Ouchi, N1
Murohara, T1
Ye, P2
Zhang, C1
Wu, SM2
Liu, YX1
Sakai, S1
Miyauchi, T1
Irukayama-Tomobe, Y1
Ogata, T1
Goto, K1
Yamaguchi, I1
Yang, W1
Sheng, L1
Nakamura, T1
Yamamoto, E1
Kataoka, K1
Yamashita, T1
Tokutomi, Y1
Dong, YF1
Matsuba, S1
Ogawa, H1
Kim-Mitsuyama, S1
Liu, Z1
Huang, F1
Xing, Z1
Wang, H1
Li, Z1
Asakawa, M1
Takano, H1
Nagai, T1
Uozumi, H1
Hasegawa, H1
Kubota, N1
Saito, T1
Masuda, Y1
Kadowaki, T1
Komuro, I1

Other Studies

12 other studies available for pioglitazone and Cardiac Hypertrophy

ArticleYear
Pioglitazone Alleviates Cardiac Fibrosis and Inhibits Endothelial to Mesenchymal Transition Induced by Pressure Overload.
    Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, 2018, Volume: 45, Issue:1

    Topics: Anilides; Animals; Cardiomegaly; Cell Differentiation; Echocardiography; Fibrosis; Hemodynamics; Hum

2018
Metabonomic profiling revealed an alteration in purine nucleotide metabolism associated with cardiac hypertrophy in rats treated with thiazolidinediones.
    Journal of proteome research, 2013, Dec-06, Volume: 12, Issue:12

    Topics: 5' Flanking Region; Adenosine Monophosphate; Adenylosuccinate Synthase; Animals; Cardiomegaly; Gene

2013
Diuretics prevent thiazolidinedione-induced cardiac hypertrophy without compromising insulin-sensitizing effects in mice.
    The American journal of pathology, 2014, Volume: 184, Issue:2

    Topics: Animals; Cardiac Volume; Cardiomegaly; Diuretics; Extracellular Signal-Regulated MAP Kinases; Furose

2014
A systems biology approach to understand the pathophysiological mechanisms of cardiac pathological hypertrophy associated with rosiglitazone.
    BMC medical genomics, 2014, Jun-17, Volume: 7

    Topics: Animals; Cardiomegaly; Diet, High-Fat; Gene Expression Profiling; Gene Expression Regulation; Genome

2014
Differential roles of cardiomyocyte and macrophage peroxisome proliferator-activated receptor gamma in cardiac fibrosis.
    Diabetes, 2008, Volume: 57, Issue:9

    Topics: Adiponectin; Angiotensin II; Animals; Cardiomegaly; Chemotaxis; Female; Fibrosis; Hypoglycemic Agent

2008
Evidence for the importance of adiponectin in the cardioprotective effects of pioglitazone.
    Hypertension (Dallas, Tex. : 1979), 2010, Volume: 55, Issue:1

    Topics: Adiponectin; AMP-Activated Protein Kinases; Angiotensin II; Animals; Blotting, Western; Cardiomegaly

2010
[Pioglitazone inhibits cardiac hypertrophy of rats in vitro and in vivo].
    Zhongguo ying yong sheng li xue za zhi = Zhongguo yingyong shenglixue zazhi = Chinese journal of applied physiology, 2005, Volume: 21, Issue:1

    Topics: Animals; Atrial Natriuretic Factor; Cardiomegaly; Cell Line; Cytokines; Disease Models, Animal; Inte

2005
Peroxisome proliferator-activated receptor-gamma activators inhibit endothelin-1-related cardiac hypertrophy in rats.
    Clinical science (London, England : 1979), 2002, Volume: 103 Suppl 48

    Topics: Analysis of Variance; Animals; Cardiomegaly; Chromans; Endothelin-1; Endothelins; Male; Natriuretic

2002
Effect of pioglitazone on the expression of inflammatory cytokines in attenuating rat cardiomyocyte hypertrophy.
    Methods and findings in experimental and clinical pharmacology, 2006, Volume: 28, Issue:10

    Topics: Angiotensin II; Animals; Anti-Inflammatory Agents; Atrial Natriuretic Factor; Cardiomegaly; Cells, C

2006
Beneficial effects of pioglitazone on hypertensive cardiovascular injury are enhanced by combination with candesartan.
    Hypertension (Dallas, Tex. : 1979), 2008, Volume: 51, Issue:2

    Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimidazoles; Biphenyl Compounds; Blood Pressur

2008
Pioglitazone inhibits hypertrophy induced by high glucose and insulin in cultured neonatal rat cardiomyocytes.
    Die Pharmazie, 2007, Volume: 62, Issue:12

    Topics: Animals; Animals, Newborn; Atrial Natriuretic Factor; Cardiomegaly; Cell Size; Cells, Cultured; Cyto

2007
Peroxisome proliferator-activated receptor gamma plays a critical role in inhibition of cardiac hypertrophy in vitro and in vivo.
    Circulation, 2002, Mar-12, Volume: 105, Issue:10

    Topics: Actins; Angiotensin II; Animals; Atrial Natriuretic Factor; Body Weight; Cardiomegaly; Cell Size; Ce

2002